Novartis AG [NVS] Revenue clocked in at $53.00 billion, down -2.39% YTD: What’s Next?

Related

Novartis AG [NYSE: NVS] traded at a high on 05/12/22, posting a 1.59 gain after which it closed the day’ session at $85.38. The company report on May 12, 2022 that Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker analysis of Piqray® plus fulvestrant.

Data for Tafinlar® + Mekinist® in pediatric patients with BRAF V600 low-grade glioma to be featured in ASCO official press briefing.

The results of the trading session contributed to over 3400917 shares changing hands. Over the past one week, the price volatility of Novartis AG stands at 1.46% while the volatility over the past one month is 1.42%.

The market cap for NVS stock reached $212.37 billion, with 2.23 billion shares outstanding and 2.15 billion shares in the current float. Compared to the average trading volume of 2.57M shares, NVS reached a trading volume of 3400917 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Novartis AG [NVS]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVS shares is $104.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wolfe Research have made an estimate for Novartis AG shares, keeping their opinion on the stock as Peer Perform, with their previous recommendation back on May 09, 2022. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on January 10, 2022, representing the official price target for Novartis AG stock.

The Average True Range (ATR) for Novartis AG is set at 1.54, with the Price to Sales ratio for NVS stock in the period of the last 12 months amounting to 4.01. The Price to Book ratio for the last quarter was 3.09, with the Price to Cash per share for the same quarter was set at 7.56. Price to Free Cash Flow for NVS in the course of the last twelve months was 37.29 with Quick ratio for the last quarter at 1.00.

How has NVS stock performed recently?

Novartis AG [NVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.96. With this latest performance, NVS shares dropped by -7.87% in over the last four-week period, additionally plugging by 2.66% over the last 6 months – not to mention a drop of -3.42% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVS stock in for the last two-week period is set at 41.19, with the RSI for the last a single of trading hit 39.90, and the three-weeks RSI is set at 43.39 for Novartis AG [NVS]. The present Moving Average for the last 50 days of trading for this stock 87.48, while it was recorded at 84.62 for the last single week of trading, and 86.41 for the last 200 days.

Novartis AG [NVS]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Novartis AG [NVS] shares currently have an operating margin of +23.11 and a Gross Margin at +69.27. Novartis AG’s Net Margin is presently recorded at +46.53.

Return on Total Capital for NVS is now 12.56, given the latest momentum, and Return on Invested Capital for the company is 27.67. Return on Equity for this stock inclined to 39.33, with Return on Assets sitting at 18.25. When it comes to the capital structure of this company, Novartis AG [NVS] has a Total Debt to Total Equity ratio set at 45.86. Additionally, NVS Total Debt to Total Capital is recorded at 31.44, with Total Debt to Total Assets ending up at 22.83. Long-Term Debt to Equity for the company is recorded at 36.25, with the Long-Term Debt to Total Capital now at 24.85.

Reflecting on the efficiency of the workforce at the company, Novartis AG [NVS] managed to generate an average of $210,515 per employee. Receivables Turnover for the company is 5.88 with a Total Asset Turnover recorded at a value of 0.39.Novartis AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.

Earnings analysis for Novartis AG [NVS]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novartis AG go to 4.71%.

Insider trade positions for Novartis AG [NVS]

There are presently around $17,657 million, or 9.60% of NVS stock, in the hands of institutional investors. The top three institutional holders of NVS stocks are: DODGE & COX with ownership of 28,249,540, which is approximately -3.473% of the company’s market cap and around 9.30% of the total institutional ownership; LOOMIS SAYLES & CO L P, holding 17,893,566 shares of the stock with an approximate value of $1.5 billion in NVS stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $1.49 billion in NVS stock with ownership of nearly -2.097% of the company’s market capitalization.

Positions in Novartis AG stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 475 institutional holders increased their position in Novartis AG [NYSE:NVS] by around 13,032,190 shares. Additionally, 526 investors decreased positions by around 21,353,124 shares, while 212 investors held positions by with 175,722,575 shares. The mentioned changes placed institutional holdings at 210,107,889 shares, according to the latest SEC report filing. NVS stock had 96 new institutional investments in for a total of 1,426,493 shares, while 81 institutional investors sold positions of 2,616,902 shares during the same period.